Sinovac issues may limit Latin American vaccine uptake
The Butantan Institute in Sao Paulo yesterday reported a 50.4% efficacy rate for Chinese Sinovac's CoronaVac vaccine
You must be signed in to read this analysis
What is this?
This summary is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
This summary refers to the following article(s).